MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1

[1] Andius P(2004)Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression BJU Int 93 980-984

[2] Holmang S(2003)A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 96-100

[3] Shahin O(2001)Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 666-675

[4] Stein JP(2010)Optimal timing of radical cystectomy in T1 high-grade bladder cancer Expert Rev Anticancer Ther 10 1891-1902

[5] Bostrom PJ(2007)Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177 75-79

[6] Herr HW(2003)The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer J Urol 169 1219-1228

[7] Donat SM(2008)Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history Rev Urol 10 31-43

[8] Dalbagni G(2007)A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans Oncogene 26 1317-1323

[9] Smith ND(2008)Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder Oncol Rep 20 49-55

[10] Pasin E(2007)Shaping genetic alterations in human cancer: the p53 mutation paradigm Cancer Cell 12 303-312

[1] Andius P(2004)Bacillus Calmette-Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression BJU Int 93 980-984

[2] Holmang S(2003)A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival J Urol 169 96-100

[3] Shahin O(2001)Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients J Clin Oncol 19 666-675

[4] Stein JP(2010)Optimal timing of radical cystectomy in T1 high-grade bladder cancer Expert Rev Anticancer Ther 10 1891-1902

[5] Bostrom PJ(2007)Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 177 75-79

[6] Herr HW(2003)The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer J Urol 169 1219-1228

[7] Donat SM(2008)Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history Rev Urol 10 31-43

[8] Dalbagni G(2007)A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans Oncogene 26 1317-1323

[9] Smith ND(2008)Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder Oncol Rep 20 49-55

[10] Pasin E(2007)Shaping genetic alterations in human cancer: the p53 mutation paradigm Cancer Cell 12 303-312